Summary. The interleukin-2 (IL-2) mini-pellet, the carrier material of which is a biocompatible and biodegradable atelocollagen refined from bovine skin, contains 1 • units of IL-2 and can release IL-2 slowly in vivo by diffusion and dissolution. We have evaluated the antitumor effects of the IL-2 mini-pellet on an established solid murine tumor, methylcholanthrene-induced fibrosarcoma (Meth A). The subcutaneous administration of the IL-2 mini-pellet alone on days 8 and 11 after tumor inoculation significantly inhibited tumor growth. A significant inhibition was also seen when it was combined with the intravenous injection of 5 x 107 lymphokine-activated killer (LAK) cells, in comparison to the untreated controls. Moreover, therapy with the IL-2 mini-pellet alone or in combination with LAK cells also prolonged the survival of mice bearing Meth A fibrosarcoma. In order to determine the precise mechanism of action of these antitumor effects, we tested splenocytes of treated mice for cytotoxic activity in vitro and investigated tumor tissues by an immunohistochemical method. On day 2 after the administration of the IL-2 mini-pellet, the lyric activity of splenocytes against both YAC-1 and JTC-11 cells (i.e. NK and LAK activity) was significantly augmented, and on day 7 a massive accumulation of lymphocytes, which were mainly like Thyl + and/or asialo-GM1 + LAK cells, was seen in the tumor. These findings indicate that the IL-2 mini-pellet is an appropriate system for local administration of IL-2 and can induce LAK-like effector cells at the target site.
Introduction
Interleukin-2 (IL-2) first was identified by Morgan et al. as a factor produced by mitogen-stimulated human T cells that mediated the selective expansion of T cells in vitro (Morgan et al. 1976) . It is a glycoprotein released by activated helper T lymphocytes and is an important mediator of the immune response (Wagner and Rollinghof 1978) . Moreover, IL-2 also is essential for the augmentation of natural killer (NK) activity (Riccardi et al. 1986 ), the expansion of cytotoxic T lymphocytes (Shaw et al. 1980) , the production of interferon-7 (Russio et al. 1987) , the generation of LAK cells, which were capable of lysing a wide variety of fresh, NK-resistant tumor targets, but not normal cells (Grimm et al. 1982) , and other antitumor activities in malignancy.
Large amounts of highly purified recombinant IL-2 have become available for in vivo studies through the genetic cloning of IL-2 and its successful insertion and expression in Escherichia coli (Taniguchi et al. 1983) . Recently the adoptive transfer of LAK cells with the concomitant administration of recombinant IL-2 and the systemic administration of high-dose IL-2 have been tried clinically and were effective in treating patients with advanced, metastatic cancer . However, since the serum half-life of IL-2 is extremely short (Donohue et al. 1983) , it is necessary to inject a large amount of IL-2 to maintain the serum concentration at a therapeutic level, and significant side-effects, for example hypotension, renal dysfunction and interstitial pulmonary edema producing respiratory compromise in some cases, have been produced as a result of the vascular leak syndrome induced by IL-2 administration (Rosenstein et al. 1986; Cotran et al. 1987) . However, these toxicities are dependent on the dose of IL-2, so they can be prevented if the serum IL-2 activity is kept low.
BecauSe of the development of powerful new drugs with significant side-effects, drug delivery systems that can suppress the side-effects and yet allow good distribution to target sites have been studied and tried clinically using many new substances as carriers. Collagen, a major protein of connective tissue in animals, is a biocompatible and biodegradable material with m a n y applications, including i m p l a n t a t i o n for cosmetic surgery, use as an absorbable suture, a n d use as hemostatic material ( R u b i n et al. 1973) . Collagen is thought to be superior to other conventional materials because of its low antigenicity a n d bioabsorbability. Therefore, we utilized the mini-pellet system m a n u f a c t u r e d by S u m i t o m o Pharmaceuticals Co. Ltd, which used atelocollagen refined from bovine skin without any organic solvent or heating process (Taken a k a et al. 1986) as the carrier, a n d developed slow delivery system for IL-2: the IL-2 mini-pellet. We have previously reported that the IL-2 mini-pellet could m a i n t a i n serum IL-2 levels for 72 h after s u b c u t a n e o u s administration in mice and that the m a x i m a l serum c o n c e n t r a t i o n of IL-2 was lower t h a n with aqueous IL-2 injection (Matsuoka et al. 1988 ). This time, by application of the IL-2 mini-pellet to the target site, we attempted to achieve high levels of c o n t i n u o u s IL-2 activity at the t u m o r site without increasing the serum IL-2 level.
In the present study, we d e m o n s t r a t e d an a n t i t u m o r effect, by the s u b c u t a n e o u s a d m i n i s t r a t i o n of the IL-2 mini-pellet near the t u m o r alone or c o m b i n e d with the intravenous injection of L A K cells, on t u m o r growth a n d survival of mice bearing Meth A fibrosarcoma. We also tested the cytotoxic activity of splenocytes obtained from treated mice. In addition, to identify the s u b p o p u l a t i o n of tumor-infiltrating cells that mediate these effects, we studied the histopathology of the tumors.
Materials and methods
Mice. Inbred 5-week-old male BALB/c mice were purchased from the Shizuoka Experimental Animal Center (Hamamatsu, Shizuoka, Japan) and were maintained under established-pathogen-free conditions in our laboratory.
Recombinant IL-2. Human recombinant IL-2 was kindly supplied by Ajinomoto Co. Ltd (Tokyo, Japan). This purified material had a specific activity of 4.82 x 10 v units/nag protein.
IL-2 mini-pellet. The IL-2 mini-pellet used in these experiments was manufactured and supplied by Sumitomo Pharmaceuticals Co. Ltd (Osaka, Japan). It is rod-shaped with a length of about 10 mm and a diameter of about 1 mm and contains 1 x 10 6 units recombinant IL-2 (Fig. 1) . Atelocollagen, which was supplied from Koken Co. Ltd (Tokyo, Japan), is used as the carrier material. It is a collagen whose telopeptides expressing its major immunogenicity have been removed by protease treatment. The IL-2 mini-pellet can be administered subcutaneously by standard injection and is biocompatible and biodegradable (Takenaka et al. 1986 ).
Splenocytes. Mice were sacrificed by cervical dislocation and their spleens were removed aseptically and minced with scissors in RPMI-1640 (Nissui Pharmaceutical Co. Ltd, Tokyo, Japan) containing 5% heat-inactivated fetal calf serum (Grand Island Biological Co. Ltd, Grand Island, NY). The cell suspension was filtered through 150-gauge nylon mesh to remove debris, and erythrocytes were lysed osmotically by an ammonium chloride/potassium buffer. The cells were then centrifuged and washed three times with RPMI-/640 containing 5% fetal calf serum.
Generation of LAK cells. Fresh splenocytes were incubated in recombinant IL-2, 1000 units/ml, in complete medium for 72 h at 37 ~ C in a moist atmosphere with 5% CO2. Complete medium consisted of RPMI-1640 with 5% fetal calf serum, 100 Ixg/ml streptomycin, 100 units/ml penicillin, 50 laM 2-mercaptoethanol, and 0.03% fresh glutamine. The cells were placed at a concentration of 2.5 x 106 cells/ml into culture flasks (Falcon no. 3024) and, after incubation, were washed three times with RPMI-1640 containing 5% fetal calf serum.
Tumor. Meth A fibrosarcoma, which was derived by the intramuscular injection of methylcholanthrene, is syngeneic to BALB/c mice. This tumor has been maintained in our laboratory. Fig. 2A , 1 x 1 0 6 Meth A fibrosarcoma cells, in single-cell suspension in 0.1 ml RPMI-1640 containing 5 % fetal calf serum, were injected as superficially as possible into the back of 6-week-old mice on day 0. Mice were divided into nine groups treated as follows: (a) no treatment, (b) mini-pellet without IL-2 (placebo) on days 8 and 11, (c) LAK cells alone on days 8 and 11, (d) 1 x 10 6 units IL-2 in phosphate-buffered saline (PBS) on days 8 and 11, (e) 1 x ][0 6 units IL-2 and LAK cells on days 8 and 11, (f) 3 x 10 s units IL-2 in PBS once daily for 6 days beginning on day 8, (g) 3 x l0 s units IL-2 for 6 days beginning on day 8 and LAK cells on days 8 and 11, (h) IL-2 mini-pellet alone on days 8 and 11, and (i) IL-2 mini-pellet and LAK cells on days 8 and 11. Placebo and the IL-2 mini-pellet were administered subcutaneously and IL-2 in PBS also was injected subcutaneously near the tumor. Samples of 5 x 1 0 7 LAK cells were injected intravenously in 0.2 ml complete medium. The perpendicular diameters of the tumors were measured daily and the tumor weights were estimated by the formula,
Experimental therapy model. As shown in
During survival experiments, the mice were followed until their death. Fig. 1 . The interleukin-2 (IL-2) mini-pellet is about 1 mm in diameter and 10 mm in length. It contains 1 x 1 0 6 units recombinant IL-2 and easily can be injected subcutaneously by a standard technique. Atelocollagen, which has little immunogenicity, is used as the carrier material
In vitro cytotoxicity assay. Cytotoxic activity was assayed in a chromium-release assay in triplicate. The NK-sensitive YAC-1 cells, which were Moloney-virus-induced lymphoma cells, and the NK-resistant JTC-11 cells, which were derived from an Ehrlich carcinoma (Ono et al. 1986 ), were used as target cells. As effector cells, splenocytes were obtained daily from mice bearing Meth A fibrosarcoma, receiving ( , 7, 7, 7, 5, 6, 5, 6 , and 6. Tumor growth was monitored by measuring the means of tumor weights calculated from two perpendicular diameters. Therapy by the IL-2 mini-pellet alone or in combination with LAK cells significantly inhibited tumor growth LAK cells on day 8. The YAC-I targets were labeled with Na2'lCrO4 (New England Nuclear, Boston, Mass) for 1 h at 37" C, washed three times and mixed with effector cells at various E : T ratios in a 96-well round-bottom plate and then incubated at 37" C in 5% COz for 4 h. The JTC-ll targets (~1 x 10 ~ cells/well) were cultured as monolayers in a 96-weli flat-bottom plate and labeled with NazS1CrO4 for 12 h after the cells had become attached. Then the cells were washed three times and the effector cells were added at various E:T ratios and incubated for 4 h. Supernatants from the cultures were harvested and counted in a gamma counter. Maximum isotope release was determined by incubation of targets with I M NaOH and spontaneous release was obtained by incubation of targets with complete medium alone. The percentage of lysis was calculated by the formula experimental release-spontaneous release (cpm) x 100 maximal release-spontaneous release (cpm) Immunohistochemical studies. Cryostat sections (6 gm thick) of tumors treated with the IL-2 mini-pellet plus LAK cells or the IL-2 mini-pellet alone were fixed in acetone for 10 min at 4~ and washed three times in PBS. Some sections were then stained with hematoxylin/eosin (H&E) while others were incubated with antibodies for 60 min at room temperature. Sections were washed three times in PBS and stained by an avidin/biotin/peroxidase method, with avidin-peroxidase conjugate and biotinized rabbit anti-mouse IgG. Peroxidase activity was detected using 0.05% 3,3'5,5'-diaminobenzidine tetrahydrochloride and 0.01% hydrogen peroxide in 0.05 M Tris/HCl buffer, pH 7.6. Sections were washed in distilled water and then poststained with hematoxylin. The antibodies used were antiThyl, anti-L3T4, anti-Lyt2 monoclonal antibodies (Becton Dickinson, Mountain View, Calif) and lyophilized anti-(asialo-GM 1) antiserum (Wako Pure Chemical Industries Ltd, Osaka, Japan). Because anti-(asialo-GMl) antibody was a rabbit antiserum, biotinized goat anti-rabbit IgG was used as a second antibody and followed by the application of avidin-peroxidase conjugate.
Statistical analysis'. Significant differences in tumor weight and in mean survival time were determined by the Mann-Whitney U-test.
Results t

Antitumor effects of the IL-2 mini-pellet plus LAK cells or the IL-2 mini-pellet alone on the growth of Meth A fibrosarcoma
The results of a typical experiment are presented in Fig. 2 B. The tumors in the groups treated by placebo, LAK cells alone, and IL-2 alone grew as rapidly as in the no-treatment group. Treatment with IL-2 plus LAK cells suppressed tumor growth whatever method was used for IL-2 injection. Furthermore, the IL-2 mini-pellet alone or the IL-2 mini-pellet plus LAK cells caused a significant inhibition of tumor growth compared to groups treated with IL-2 plus LAK cells (the mean tumor weight on day 38 after tumor inoculation was 2.29 _+ 0.80 g with the IL-2 mini-pellet alone and 1.38 4-1.04 g when combined with LAK cells versus 9.01_+6.44 g with 1 x 106 units IL-2 plus LAK cells and 7.43_+3.30 g with 3 x 106 units IL-2 for 6 days plus LAK cells, respectively; P<0.05 in all comparisons). In mice receiving the IL-2 mini-pellet alone, the tumor growth curve remained flat beginning 4 or 5 days after administration, while in the group treated with the IL-2 mini-pellet plus LAK cells transient tumor regression was observed in all mice immediately after the a l X 106 Meth A fibrosarcoma cells were injected intradermatly into mice on day 0. The mice were divided into 9 groups, and therapy was begun on day 8 b Mean comparison between the no treatment and treatment groups c Placebo was administered subcutaneously near the tumor on days 8 and 11 a 5 x 107 LAK cells were injected intravenously on days 8 and 11 e ] X 106 units of IL-2 was injected subcutaneously near the tumor on days 8 and 11 f 3 x 105 units of IL-2 was injected subcutaneously daily near the tumor for 6 days beginning on day 8 g The IL-2 mini-pellet was administered subcutaneously near the tumor on days 8 and 11 h Complete remission beginning of therapy. Soon after starting administration there was a difference between the effects of these two protocols (on day 18, 0.524-0.09 g with the IL-2 minipellet alone versus 0.25 4-0.19 g for the combination with LAK cells; P<0.05). However, from day 21 the IL-2 mini-pellet both alone and in combination with LAK cells inhibited tumor growth similarly. These results suggested that the IL-2 mini-pellet alone was sufficiently effective, even in comparison with IL-2 plus LAK cells or the IL-2 mini-pellet plus LAK cells.
Antitumor effects of the IL-2 mini-pellet plus LAK cells' or the IL-2 mini-pellet alone on the survival of mice bearing Meth A fibrosarcoma
As shown in Table 1 , when mice received 1 x 106 units IL-2 plus LAK cells or 3 x 105 units IL-2 for 6 days plus LAK cells, there was a significant survival increase compared with untreated controls (the median survival times of 46.6_+8.1 days and 42.24-8.8 days versus 33.04-4.7 days, respectively; P<0.05). When the IL-2 mini-pellet was used, a significant survival increase over untreated controls was seen (the median survival time of 50.5 4-17.5 days versus 33.0 4-4.7 days; P < 0.05). The IL-2 mini-pellet also induced a minimal increase in survival over IL-2 plus LAK cells, with one of six mice surviving beyond 80 days (the median survival time of 50.5 4-17.5 days versus 46.6_+8.1 days and 42.2+8.8 days, respectively: P not significant). When the combination of the IL-2 mini-pellet plus LAK cells was used, there was survival benefit compared to untreated controls (the median survival time of 53.3 4-16.0 days; P<0.05), and the tumor regressed completely in one of six mice. However, this combined therapy brought about no improvement in the duration of survival compared with the IL-2 mini-pellet alone. Thus, the antitumor effect of the IL-2 mini-pellet alone on survival was equivalent to that of IL-2 plus LAK cells or the IL-2 mini-pellet plus LAK ceils. Fig. 3 . The peak augmentation of LAK activity also occurred 2 days after treatment
Cytotoxic activity of splenocytes obtained [?om cancer-bearing mice treated with the IL-2 mini-pellet
Representative experiments are shown in Figs. 3 and 4. N K activity against NK-sensitive YAC-1 began to increase on day 1 after the administration and reached a peak on day 2 in both the group treated by the IL-2 minipellet alone and the group treated by the IL-2 mini-pellet plus LAK cells. However, the administration of an additional IL-2 mini-pellet on day 3 did not induce lytic activity like that seen after the initial administration, and by day 7, cytotoxic activity had returned to the pretreatment level. LAK activity against NK-resistant JTC-11 showed changes similar to those in N K activity. When N K activity and LAK activity reached the peak on day 2, the activity in the group receiving LAK cells was higher than in the group which received the IL-2 mini-pellet alone.
Histopathological analysis of the tumor after the administration of the IL-2 mini-pellet
Tumors treated by the IL-2 mini-pellet plus LAK cells or the IL-2 mini-pellet alone were removed surgically on days 1 and 7, and were frozen until used. When the IL-2 mini-pellet and LAK cells were given, we found that inflammatory cells, which were mostly lymphocytes, had 145 accumulated around the tumor and invaded it on day 1, as seen by H&E staining. Phenotypic analysis using monoclonal antibodies showed that these cells were mainly Thyl § cells and asialo-GM1 + cells, whereas anti-L3T4 or anti-Lyt2 antibodies stained a few tumor-infiltrating lymphocytes (data not shown). In contrast, there were few if any lymphocytes in tumors from mice treated by the IL-2 mini-pellet alone. However, when an additional IL-2 mini-pellet was administrated on day 3, a massive accumulation of inflammatory cells, mainly lymphocytes, was documented on day 7 and tumor cells were detached and killed (Fig. 5) . The majority of these lymphocytes bore Thyl or asialo-GM1 markers (Fig. 6 ). For comparison, when placebo was given, no lymphocytes were seen around the tumor even on day 7 (Fig. 5 ).
Discussion
As a form of immunotherapy for patients with advanced cancer, the in vivo administration of LAK cells in combination with IL-2 is being used currently in several clinical trials, and partial or complete regression of tumor metastases has been noted in some cases . This approach requires the transfer of large numbers of LAK cells and the systemic injection of IL-2. However, since it is difficult to obtain a large number of lymphocytes from patients for adoptive immunotherapy, the administration of IL-2 alone also has been employed clinically. Recent investigations have shown that exogenously administered IL-2 can lead to the genesis of LAK cells from endogenous lymphocytes (Hank et al. 1988) . However, there is a serious problem with the clinical used of IL-2, in that IL-2 is cleared rapidly and the initial halflife is less than I h (Donohue and Rosenberg 1983) . Although relatively high doses of IL-2 have been administered to maintain adequate serum IL-2 activity by intravenous injection every 8 h or by constant infusion (West et al. 1987) , therapy has been associated with many toxic reactions (Rosenstein et al. 1986; Cotran et al. 1987) . Because of these side-effects, we considered the systemic administration of IL-2 to have a limit both in terms of dose and length of treatment and, therefore, a more effective route of administration of IL-2 should be found. We regarded the local administration of IL-2 as a possible alternative to systemic IL-2 therapy to gain direct access to the target site without high serum IL-2 activity. In recent years, as rapid progress has been made in the manufacture of powerful new drugs and the purification of bioactive substances like interferon, tumor necrosis factor, and interleukin, drug delivery systems have been developed to increase their efficacy and minimize their side-effects. With regard to IL-2, slow-release administration using an osmotic mini-pump has also been reported (Nishimura et al. 1986 ). However, it is hard to achieve the practical application of this system clinically, since the mini-pump has to be removed after IL-2 delivery. In addition, the size of a mini-pump containing a significant quantity of IL-2 must necessarily be quite large. In the light of this, we chose a mini-pellet that used a bioabsorbable atelocollagen derived from highly purified bovine dermal collagen as the carrier material. A gel mixture of IL-2 and the atelocollagen was molded into cylindrical mini-pellets. Using this process, the shape of the IL-2 mini-pellet could be altered easily if desired.
Previously we reported that the IL-2 mini-pellet decreased the peak of serum IL-2 concentration in comparison with the aqueous ~olution of IL-2 to 1 x 104 units/ml and also prolonged the duration of detectable serum IL-2 activity to 72 h (Matsuoka et al. 1988) . Because the effects of IL-2 administered in vivo have been shown to correlate with the length of time IL-2 is detectable in serum rather than the peak level (Cheever et al. 1985) , the efficacy of the IL-2 mini-pellet is acceptable, and we expect that locally at the site where the IL-2 mini-pellet is administered, IL-2 may be released slowly by diffusion from the collagen and higher IL-2 activity maintained longer.
In the experimental therapeutic model, treatment was begun on day 8 when all tumors became palpable (7-8-mm diameter) and the IL-2 mini-pellet was administered on days 8 and 11, on the basis that serum IL-2 activity was detectable for 3 days after administration. The IL-2 mini-pellet alone and in combination with LAK cells resulted in marked reductions in tumor growth, not only compared to untreated controls but also compared to IL-2 plus LAK cells. Immediately after the initiation of treatment, the inhibitory effect of the IL-2 mini-pellet alone on tumor growth was inferior to the combination of the IL-2 mini-pellet plus LAK cells, as transient tumor regression was observed in the combined case. However, the growth curves of both groups were similar over the long term and the antitumor activity was considered equivalent. The effectiveness of IL-2 plus LAK cells and the IL-2 mini-pellet plus LAK cells was demonstrated by a significant prolongation of the median survival time of mice bearing Meth A fibrosarcoma. Moreover, the IL-2 mini-pellet alone also resulted in a substantial increase in survival time compared to untreated controls. These observations, which indicated that the administration of the IL-2 mini-pellet alone was sufficiently effective both against tumor growth and for prolonging overall survival, could be relevant for future clinical trials because for this mode of therapy neither complicated injections of IL-2 nor adoptive transfer of cultured cells was necessary.
To identify more directly the mechanism of action, we obtained splenocytes from mice treated by the IL-2 minipellet alone or in combination with LAK cells to be used as effector cells and studied the lytic activity against YAC-1, as a standard NK target, and JTC-11, as a standard LAK target. In both groups NK or LAK activity began to increase on day 1 after administration, and peak activity occurred on day 2. When an additional IL-2 mini-pellet was administered on day 3, neither NK nor LAK activity was augmented as intensely as after the initial administration and it declined to the pretreatment level by day 7. Because the suppression of tumor growth continued for at least 7 days, antitumor activity was felt to be due more to local effects than to systemic augmentation of cytotoxic activity.
The local effect on the tumor was evaluated by immunohistochemical examination. When the IL-2 mini-pellet was administered alone, tumor-infiltrating lymphocytes increased gradually and on day 7 a number ofThyl § cells and asialo-GM1 § cells were observed in the tumor with widespread destruction of tumor cells. LAK cells are now generally considered to be a heterogeneous effector cell population, derived largely from NK cell precursors (Herberman et al. 1987) . Rosenberg et al. have reported that the majority of early LAK effector cells are Thyl § L3T4-, Lyt2-, and asialo-GM1 + (Mule et al. 1987) . Therefore, the fact that these effector cells evolved relatively quickly and were mainly Thyl § cells and asialo-GM1 + cells indicated that they might be LAK cells (especially activated NK cells) that had been generated in vivo.
The results reported here form a basic study concerning the antitumor activity of the IL-2 mini-pellet and its mechanism of action in mice. Since the variety of side-effects associated with IL-2 therapy have now been reported, we believe that this IL-2 slow delivery system, the IL-2 mini-pellet, will prove to be an extremely effective means for the local administration of IL-2. We are now planning to apply the IL-2 mini-pellet to transcatheter arterial embolization therapy as an embolus material in patients with unresectable primary hepatocellular carcinomas and multiple metastatic liver tumors, and hope to begin this clinical trial in the near future.
